Compare BioNano Genomics Inc (BNGO) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Celsius Holdings, Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Celsius Holdings, Inc. trades at $27.11 (market cap $7.11B). The key difference: Celsius Holdings, Inc. is far larger — about 520.5× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | CELH | |
|---|---|---|
Market Cap | $13.66M | $7.11B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $64.86 |
52-Week Low | $1.06 | $23.77 |
Enterprise Value | $16.26M | $8.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
CELH trades at $27.21, down 2.02% on the day, with technical indicators signaling a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates of $0.4139, while revenue grew 11% year-over-year. Recent news highlights leadership changes and an ongoing shareholder investigation. The stock faces pressure from slowing core-brand growth but benefits from strong analyst support and a partnership with PepsiCo.
Outlook: High growth potential via international expansion and PepsiCo distribution, but execution risks and margin pressures persist. Risks include competitive threats and delayed growth projections. Analyst consensus is strongly bullish with a $44.08 price target, suggesting significant upside if operational challenges are overcome.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
